65,437 trials
Acute Myeloid Leukemia
Primary: Percentage of Patients With Overall Complete Response for Stage I — 35.4; 11.5 percentage of participants
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
Blunt Thoracic Aortic Injury
Primary: All-cause Mortality Within 30-days of the Index Procedure — 4 participants
Actinic Keratosis
Primary: Complete Clearance of AKs at Week 11 — 101; 80 participants
Myopia · Refractive Error
Primary: Subjective Rating of Overall Satisfaction — 7.45; 6.91 Units on a scale
Cancer · Colon Cancer · Colorectal Cancer
Primary: Progression-free Survival (PFS) — 7.7; 9.2; 3.7; 6.4 months
Binge Eating Disorder · Obesity
Primary: Frequency of Binge Eating Episodes — 0.8; 1.0 episodes/week
Stress Disorders, Post-Traumatic
Primary: Post-Traumatic Stress Disorder Checklist-Military Version (PCL-M) — 63.08; 61.71; 42.83; 51.65 units on a scale
Cataract
Primary: Mesopic Monocular Contrast Sensitivity Without Glare 1.5 and 3 Cycles/Degree — 1.494; 1.576; 1.410; 1.613 log contrast sensitivity units
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.0; 22.0 mm Hg
Viral Hepatitis B · Contraception · Breast Feeding, Exclusive
Primary: Utilization of Postpartum Contraception — 199; 213 participants — p=<0.05
Refractive Error
Primary: Contact Lens-Corrected Distance Monocular Snellen Visual Acuity (VA) (20/30 or Better) — 100.0; 100.0; 100.0; 98.0 Percentage of eyes
Cosmetic Appearance
Primary: Overall Preference — 49.1; 24.6 Percentage of participants
Myopia
Primary: Subjective Rating of Overall Comfort — 8.7; 8.6; 8.7; 8.5 Units on a scale